Breaking News: Terns Pharmaceuticals Raises $172.7M in Funding for Clinical-Stage Small-Molecule Product Pipeline

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapies to combat serious diseases, has successfully raised $172.7 million in its latest funding round. This significant financial boost will enable Terns to accelerate the advancement of its robust pipeline, which includes three active clinical-stage development programs aimed at tackling pressing health issues such as oncology and obesity. Among these promising candidates are an allosteric BCR-ABL inhibitor, which targets specific forms of leukemia, and a small-molecule GLP-1 receptor agonist designed to aid in weight management. Furthermore, the funding will support the ongoing development of a THR-β agonist as well as preclinical GIPR modulator programs, both of which hold high potential in transforming the treatment landscape for patients affected by metabolic disorders. Terns is poised to build upon this momentum, with plans to utilize these funds for clinical trials, research, and expanding its professional team. The company’s commitment to innovation and discovery reflects its mission to deliver impactful solutions that enhance patient outcomes. As Terns Pharmaceuticals continues to forge ahead, it welcomes the opportunity to collaborate with investors and partners who share its vision of addressing some of the most challenging health problems faced today. For more information about their groundbreaking work, please visit www.ternspharma.com.